ANI Pharmaceuticals Earnings Calls

Q1 2025 Beat
$1.70 (24.09%)
Release date May 09, 2025
EPS estimate $1.37
EPS actual $1.70
EPS Surprise 24.09%
Revenue estimate 188.734M
Revenue actual 197.122M
Revenue Surprise 4.44%
Q4 2024 Beat
$1.63 (15.60%)
Release date Feb 28, 2025
EPS estimate $1.41
EPS actual $1.63
EPS Surprise 15.60%
Revenue estimate 169.962M
Revenue actual 190.574M
Revenue Surprise 12.13%
Q3 2024 Beat
$1.34 (22.94%)
Release date Nov 08, 2024
EPS estimate $1.09
EPS actual $1.34
EPS Surprise 22.94%
Revenue estimate 175.118M
Revenue actual 148.332M
Revenue Surprise -15.30%
Q2 2024 Beat
$1.02 (9.68%)
Release date Aug 06, 2024
EPS estimate $0.93
EPS actual $1.02
EPS Surprise 9.68%
Revenue estimate 129.05M
Revenue actual 138.04M
Revenue Surprise 6.97%

Last 4 Quarters for ANI Pharmaceuticals

Below you can see how ANIP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 06, 2024
Fiscal end date Jun 30, 2024
Price on release $63.29
EPS estimate $0.93
EPS actual $1.02
EPS surprise 9.68%
Date Price
Jul 31, 2024 $65.72
Aug 01, 2024 $63.85
Aug 02, 2024 $61.01
Aug 05, 2024 $59.16
Aug 06, 2024 $63.29
Aug 07, 2024 $57.01
Aug 08, 2024 $56.43
Aug 09, 2024 $57.90
Aug 12, 2024 $59.68
4 days before -3.70%
4 days after -5.70%
On release day -9.92%
Change in period -9.19%
Q3 2024 Beat
Release date Nov 08, 2024
Fiscal end date Sep 30, 2024
Price on release $61.44
EPS estimate $1.09
EPS actual $1.34
EPS surprise 22.94%
Date Price
Nov 04, 2024 $56.01
Nov 05, 2024 $57.31
Nov 06, 2024 $58.40
Nov 07, 2024 $58.38
Nov 08, 2024 $61.44
Nov 11, 2024 $61.74
Nov 12, 2024 $61.00
Nov 13, 2024 $59.83
Nov 14, 2024 $58.91
4 days before 9.69%
4 days after -4.12%
On release day 0.488%
Change in period 5.18%
Q4 2024 Beat
Release date Feb 28, 2025
Fiscal end date Dec 31, 2024
Price on release $61.89
EPS estimate $1.41
EPS actual $1.63
EPS surprise 15.60%
Date Price
Feb 24, 2025 $55.57
Feb 25, 2025 $54.51
Feb 26, 2025 $55.01
Feb 27, 2025 $54.58
Feb 28, 2025 $61.89
Mar 03, 2025 $58.46
Mar 04, 2025 $59.13
Mar 05, 2025 $59.68
Mar 06, 2025 $61.05
4 days before 11.37%
4 days after -1.36%
On release day -5.54%
Change in period 9.86%
Q1 2025 Beat
Release date May 09, 2025
Fiscal end date Mar 30, 2025
Price on release $66.30
EPS estimate $1.37
EPS actual $1.70
EPS surprise 24.09%
Date Price
May 05, 2025 $72.56
May 06, 2025 $70.27
May 07, 2025 $70.82
May 08, 2025 $71.53
May 09, 2025 $66.30
4 days before -8.63%
4 days after 0%
On release day 0%
Change in period -8.63%

ANI Pharmaceuticals Earnings Call Transcript Summary of Q1 2025

Summary of ANI Pharmaceuticals Q1 2025 Earnings Call for Investors

1. Strong Financial Performance: ANI Pharmaceuticals reported record revenues of $197.1 million, up 43% year-over-year. Adjusted non-GAAP EBITDA was $50.7 million, and adjusted EPS increased to $1.70 compared to $1.21 in Q1 2024.

2. Updated Guidance for 2025:

  • Total revenues projected to be between $768 million to $793 million, an increase from prior guidance of $756 million to $776 million.
  • Adjusted non-GAAP EBITDA guidance raised to $195 million to $205 million from previous estimates of $190 million to $200 million.
  • Cortrophin Gel revenues forecasted at $265 million to $274 million, reflecting growth of 34% to 38% year-over-year.
  • ILUVIEN and YUTIQ revenues expected to be between $97 million to $103 million.

3. Cortrophin Gel Performance:

  • Revenues grew to $52.9 million in Q1 2025, up 43% year-over-year.
  • The product is experiencing strong growth across multiple specialties, particularly in rheumatology and ophthalmology, with a record number of new patients starting treatment.
  • The introduction of a pre-filled syringe for Cortrophin is anticipated to improve convenience and might attract more prescribers.

4. Generics Business Growth:

  • Generics revenues reached $98.7 million, a 41% increase YoY.
  • Significant contributions from product launches, notably Prucalopride, have driven growth.
  • ANI expects mid double-digit growth from the generics segment following a strong quarter.

5. Challenges in Retina Products:

  • ILUVIEN and YUTIQ generated $16.1 million in Q1, with U.S. performance impacted by Medicare challenges and turnover in the sales force.
  • Management is optimistic, noting positive trends in April and a commitment to improving market access through specialized pharmacy options and educational programs.

6. Tariff Situation:

  • ANI is well positioned, with over 90% of revenue generated from products manufactured in the U.S., minimizing reliance on foreign imports, especially from China.

7. Management Insights:

  • The team emphasized their commitment to expanding the Cortrophin franchise and managing challenges as they arise, while expressing confidence in their long-term strategies regarding all products.

8. Upcoming Obligations:

  • ANI is preparing for an upcoming trial regarding a royalty action against CG Oncology, which is set for July 21, 2025.

Conclusion

ANI Pharmaceuticals reported a robust Q1 2025 and provided an optimistic outlook for the year, primarily driven by growth in Cortrophin Gel, the generics segment, and strategic plans to address challenges in their retina business. The management team remains focused on executing their growth strategy while maintaining a strong balance sheet. Investors should consider the positive revenue trends, the strategic initiatives in place, and potential market expansion when evaluating ANI's stock.

ANI Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for ANIP?
ANI Pharmaceuticals (ANIP) has scheduled its earnings report for Aug 05, 2025 before the markets open.

What is the ANIP price-to-earnings (P/E) ratio?
ANIP P/E ratio as of May 09, 2025 (TTM) is -74.35.

What is the ANIP EPS forecast?
The forecasted EPS (Earnings Per Share) for ANI Pharmaceuticals (ANIP) for the first fiscal quarter 2025 is $1.58.

What are ANI Pharmaceuticals's retained earnings?
On its balance sheet, ANI Pharmaceuticals reported retained earnings of $197.12 million for the latest quarter ending Mar 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ANI PHARMACEUTICALS
ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development a...
GOLDEN STAR
Ticker Change Signal Date
BAX
$30.72
0.586% May 07
HBM
$7.41
4.05% May 05
P
PENG
$17.23
2.21% May 05
A
AORT
$23.77
21.62% May 05
PODD
$257.01
20.88% May 02

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE